Artículos por temáticas
En este apartado encontrará una actualización mensual de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por la International Parkinson & Movement Disorder Society.
FILTRAR POR:
Tema
159604 ARTíCULOS , VIENDO DEL 2041 AL 2055
Tau immunotherapy in Alzheimer's disease and progressive supranuclear palsy
Karimi N, Bayram Çatak F, Arslan E, Saghazadeh A, Rezaei N.
Int Immunopharmacol. 2022 Dec;113(Pt B):109445. doi: 10.1016/j.intimp.2022.109445. Epub 2022 Nov 18.
0
0
0
Targeting Alzheimer's Disease: The Critical Crosstalk between the Liver and Brain
Huang Z, Lin HWK, Zhang Q, Zong X.
Nutrients. 2022 Oct 14;14(20):4298. doi: 10.3390/nu14204298.
0
0
0
van den Bos MAJ, Menon P, Vucic S.
Expert Rev Neurother. 2022 Nov-Dec;22(11-12):981-993. doi: 10.1080/14737175.2022.2170784.
0
0
0
Morató X, Pytel V, Jofresa S, Ruiz A, Boada M.
Int J Mol Sci. 2022 Aug 18;23(16):9305. doi: 10.3390/ijms23169305.
0
0
0
A Revisit to Etiopathogenesis and Therapeutic Strategies in Alzheimer's Disease
Kumar M, Bansal N.
Curr Drug Targets. 2022;23(5):486-512. doi: 10.2174/1389450122666211118125233.
0
0
0
Niu TT, Yuan BY, Liu GZ.
Eur Rev Med Pharmacol Sci. 2022 Dec;26(24):9502-9510. doi: 10.26355/eurrev_202212_30702.
0
0
0
TFEB in Alzheimer's disease: From molecular mechanisms to therapeutic implications
Gu Z, Cao H, Zuo C, Huang Y, Miao J, Song Y, Yang Y, Zhu L, Wang F.
Neurobiol Dis. 2022 Oct 15;173:105855. doi: 10.1016/j.nbd.2022.105855. Epub 2022 Aug 27.
0
0
0
Targeting Necroptosis as a Promising Therapy for Alzheimer's Disease
Zhao W, Liu Y, Xu L, He Y, Cai Z, Yu J, Zhang W, Xing C, Zhuang C, Qu Z.
ACS Chem Neurosci. 2022 Jun 15;13(12):1697-1713. doi: 10.1021/acschemneuro.2c00172. Epub 2022 May 23.
0
0
0
Applications of CRISPR-Cas9 in Alzheimer's Disease and Related Disorders
De Plano LM, Calabrese G, Conoci S, Guglielmino SPP, Oddo S, Caccamo A.
Int J Mol Sci. 2022 Aug 5;23(15):8714. doi: 10.3390/ijms23158714.
0
0
0
Sala-Vila A, Satizabal CL, Tintle N, Melo van Lent D, Vasan RS, Beiser AS, Seshadri S, Harris WS.
Nutrients. 2022 Jun 9;14(12):2408. doi: 10.3390/nu14122408.
0
0
0
AXS-05: an investigational treatment for Alzheimer's disease-associated agitation
Ward K, Citrome L.
Expert Opin Investig Drugs. 2022 Aug;31(8):773-780. doi: 10.1080/13543784.2022.2096006. Epub 2022 Jul 6.
0
0
0
Nanoparticles-based anti-aging treatment of Alzheimer's disease
Chu JJ, Ji WB, Zhuang JH, Gong BF, Chen XH, Cheng WB, Liang WD, Li GR, Gao J, Yin Y.
Drug Deliv. 2022 Dec;29(1):2100-2116. doi: 10.1080/10717544.2022.2094501.
0
0
0
Anti-amyloid agents for treating incipient Alzheimer's disease: a new hope?
Loureiro JC, Silva LFAL, Pais MV, Forlenza OV.
Braz J Psychiatry. 2022 Aug 20;44(4):368-369. doi: 10.47626/1516-4446-2022-2503.
0
0
0
Potential of astrocytes in targeting therapy for Alzheimer's disease
Bi W, Lei T, Cai S, Zhang X, Yang Y, Xiao Z, Wang L, Du H.
Int Immunopharmacol. 2022 Dec;113(Pt A):109368. doi: 10.1016/j.intimp.2022.109368. Epub 2022 Oct 29.
0
0
0
Comentarios
En ningún caso la información facilitada constituye asesoramiento por parte de Zambon
Con el aval de:
En colaboración con:
